Effect of sodium-glucose co-transporter 2 inhibitor on contrast-induced acute kidney injury and prognosis in type 2 diabetes patients undergoing percutaneous coronary intervention
Chronic administration of dapagliflozin can reduces the risk of CIAKI and improves long-term cardiovascular outcomes in T2DM patients undergoing PCI. These findings support its potential use as adjunctive therapy to mitigate kidney injury and improve prognosis in this high-risk population.
Authors
- Naikuan Fu (ORCID: https://orcid.org/0000-0001-8985-6486)
- Shicheng Yang (ORCID: https://orcid.org/0000-0002-9083-5575)
- Xiangwei Zhai (ORCID: https://orcid.org/0000-0003-2967-5573)
- Peng Zhang (ORCID: https://orcid.org/0000-0001-5536-0255)
- Huifang Hao (ORCID: https://orcid.org/0000-0002-9680-8308)
Institutions
- Tianjin University (CN)
- TEDA International Cardiovascular Hospital (CN)
- Tianjin Chest Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-03-05
- DOI
- https://doi.org/10.3389/fmed.2025.1552539
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29